For 2QFY2016, IPCA Laboratories (IPCA) posted in line sales while the net profit came in lower than our estimates. The company posted a 4.7% yoy decline in sales to Rs739cr V/s Rs750cr expected, on back of domestic and exports posting a dip of 2.3% yoy and 6.9% yoy, respectively. On the operating front, the EBITDA margin came in at 10.6% V/s 11.4% expected and V/s 16.7% in 2QFY2015, owing to lower than expected sales. Thus, the Adj. net profit came in at Rs31cr V/s Rs41cr expected and V/s Rs68cr in 2QFY2015, a yoy dip of 54.3%. While the current performance of the company is being impacted due to its key plants being under the USFDA scanner, we believe once out of it, the company can bounce back to its normalized ROE of 25%. Thus, we maintain our Buy on the stock. Results lower than expectations: The company, posted an 4.7% de-growth in sales to end the period at Rs739cr V/s Rs750cr expected and Rs775cr in 2QFY2015, on back of domestic and exports posting a dip of 2.3% and 6.9% respectively. In domestic markets (Rs364cr), posted a dip of 2.3% yoy, mainly on back a tepid formulation sales (Rs331cr), a yoy...